Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,409 across all filing types
Latest filing 2016-02-18 Earnings Release
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
FY results 2015
Earnings Release Classification · 95% confidence The document is an earnings release from Innate Pharma SA for the fiscal year 2015. It contains key financial highlights, a summary of the income statement, pipeline updates, and corporate developments. While it includes financial data, it is structured as a press release (indicated by the 'Marseille, France, February 18, 2016' dateline and contact information) rather than a full statutory Annual Report (10-K). It provides the initial announcement of the annual results, fitting the definition of an Earnings Release (ER). FY 2015
2016-02-18 English
Résultats annuels 2015
Earnings Release Classification · 95% confidence The document is dated February 18, 2016, and explicitly announces 'ses résultats financiers pour 2015' (its financial results for 2015). It contains a detailed summary of key financial figures for the fiscal year ending December 31, 2015, including revenue, operating expenses, and net loss, presented in a comparative table against 2014. It also discusses clinical trial progress and corporate events that occurred during 2015 and early 2016. Since it covers a full fiscal year (2015) with comprehensive financial data, it aligns best with the Annual Report (10-K) definition, although it is presented as a press release ('communiqué de presse'). However, given the comprehensive nature of the financial data provided (including a full IFRS table for the year), it is a primary financial report for the year. If this were a 10-K, the full document would be much longer and filed with the SEC. Since this is a press release format detailing full-year results, it is most accurately classified as an Earnings Release (ER) or potentially an Interim/Quarterly Report (IR) if the company typically issues a separate, more detailed 10-K. Since it covers the *full year* and includes a detailed financial table, it is more substantial than a typical ER. In the context of European filings where a formal 10-K equivalent might not be the primary release, this comprehensive annual financial summary is closest to an Earnings Release (ER) or a very detailed Interim Report (IR) if the company doesn't issue a full Annual Report document separately. Given the title 'résultats financiers pour 2015' and the detailed financial breakdown, it functions as the primary release of annual results. If the document were significantly longer and contained all required regulatory disclosures (like a full 10-K), it would be 10-K. As a press release announcing the full-year results, ER is the most appropriate fit among the choices, as it summarizes the year's performance, even though it's comprehensive. It is not an IR because IR is for periods shorter than a year. It is not an RPA because it *is* the results announcement, not just an announcement *of* the results being published elsewhere. Therefore, ER is the best fit for a comprehensive annual results press release. FY 2015
2016-02-18 French
Start of Phase I trial of monalizumab in combination with durvalumab
Investor Presentation Classification · 95% confidence The document is a press release dated February 8, 2016, announcing the start of a Phase I clinical trial for a drug called monalizumab in combination with durvalumab. It details the study design, rationale, partnership with AstraZeneca, and provides background on the drug and the company (Innate Pharma). This type of announcement, focusing on clinical trial progress and scientific updates, is characteristic of an Investor Presentation (IP) or a general regulatory/investor communication. Since it is a detailed announcement about ongoing clinical development and partnership terms, it fits best under Investor Presentation (IP) which often includes such scientific and strategic updates, rather than a brief Earnings Release (ER) or a formal regulatory filing like 10-K or IR. It is not a transcript (CT), a management discussion (MDA), or a simple dividend notice (DIV). Given the depth of scientific and partnership detail, IP is the most appropriate classification.
2016-02-08 English
Démarrage de l'essai de Phase I monalizumab avec durvalumab
Regulatory Filings Classification · 95% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and is dated February 8, 2016. It announces the start of a Phase I clinical trial for a drug combination (monalizumab with durvalumab). This type of announcement, detailing operational progress, clinical trial initiation, and partnership updates, is characteristic of an initial public disclosure of significant corporate news, often released before a formal, comprehensive regulatory filing like a 10-K or IR. Since it is a press release announcing a specific corporate event (clinical trial start) and not a transcript (CT), a formal financial report (10-K, IR), or a proxy statement (DEF 14A), it fits best under the general category for regulatory announcements that don't fit elsewhere, which is Regulatory Filings (RNS). It is not a Report Publication Announcement (RPA) because it is the primary announcement of the news itself, not an announcement *about* the publication of a separate, attached report.
2016-02-08 French
Number of shares and voting rights of Innate Pharma as at Feb 3, 2016
Share Issue/Capital Change Classification · 95% confidence The document explicitly states its purpose: 'NUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS AT FEBRUARY 3, 2016'. It cites French regulatory articles (L. 233-8 II of the French « Code de Commerce » and article 223-16 of the AMF charter) requiring the disclosure of total shares outstanding and voting rights. This type of mandatory disclosure regarding the total number of shares and voting power, often released monthly or periodically, does not fit neatly into the primary financial report categories (10-K, IR, ER). It is a specific regulatory update concerning capital structure/shareholder information. While it relates to share capital, it is not a general share issue announcement (SHA) or a transaction in own shares (POS). It is a mandatory disclosure of the current share count for regulatory compliance. Given the options, this specific regulatory disclosure about the total number of shares and voting rights is best categorized as a general Regulatory Filing (RNS), as it is a specific, periodic regulatory requirement that doesn't match the other detailed categories like DIRS (Director's Dealing) or MRQ (Major Shareholding Notification, which usually reports a change in ownership percentage, not the total count itself). However, since the document is a formal announcement of a specific regulatory metric (share count/voting rights) required by the AMF, and it is not a report itself, RNS is the most appropriate fallback, although it is a very specific type of regulatory filing.
2016-02-05 English
Nombre d'actions et droits de vote d'Innate Pharma au 03/02/16
Share Issue/Capital Change Classification · 95% confidence The document is a press release from Innate Pharma dated February 5, 2016, announcing the 'NOUVEAU NOMBRE D'ACTIONS ET DE DROITS DE VOTE' (New number of shares and voting rights) as of February 3, 2016. It explicitly cites compliance with French commercial code (Code de Commerce) and AMF (Autorité des marchés financiers) regulations regarding the publication of the total number of shares composing the capital and the associated voting rights. This type of mandatory disclosure regarding the total share count and voting power, often triggered by crossing ownership thresholds or for regulatory reporting, aligns best with the 'Major Shareholding Notification' (MRQ) category, which covers changes in significant share ownership levels or related capital structure disclosures required by regulators. Although it is a press release, its core content is a formal regulatory disclosure about the capital structure, making MRQ more specific than a general RPA or RNS.
2016-02-05 French

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.